Arbeitsgemeinschaft
für angewandte
Humanpharmakologie e.V

Association for
Applied Human
Pharmacology

GesellschaftAnnual MeetingStudy NurseFortbildungArchiv
  

> Annual Meeting > Annual Meetings - Übersicht > Annual Meeting 2005 > Präsentationen 2005 

Präsentationen Annual Meeting 2005

 

Session I: Why do we need Phase I studies?

W. Seifert, Berlin

Is-Phase-I-useful-Seifert.pdf

Is Phase I useful?

415 K

H. Fuder, Mulhouse

Healthy-volunteers-or-patients-Fuder.pdf

Healthy volunteers or patients as target population in Phase I trials?

4.0 M

H. Caplain, Paris

Stop-dose-escalation-Caplain.pdf

When to stop dose escalation - MTD or MLD or ?

1.1 M

 

Session II: Implications of the new EU-Directive on clinical trials

A. Patat, Paris

EU-Directive-France-Patat.pdf

France

210 K

R. Frey, Wuppertal

EU-Directive-Germany-Frey.pdf

Germany

239 K

S. Warrington, London

EU-Directive-UK-Warrington.pdf

United Kingdom

442 K

J. van Gerven, Leiden

EU-Directive-Netherlands-van-Gerven.pdf

The Netherlands

0.9 M

C. Reh, Berlin

EU-Directive-Central-Europe-Reh.pdf

Central Europe

309 K

A. Patat, Paris

Comparisons-between-European-countries-Patat.pdf

Comparison between European countries

438 K

 

Session III: Safety issues in Phase I studies

M. Sibille, Lyon

Is-Phase-I-safe-Sibille.pdf

Is Phase I safe?

228 K

B. Reigner, Basel

First-dose-and-escalation-Reigner.pdf

First dose and dose escalation

121 K

G. Sanderink, Paris


Allometric scaling
No presentation available

 

Session IV: New tools in early drug development

E. Fuseau, Aix-en-Provence

PKPD-in-early-development-Fuseau.pdf

When and how does PK/PD modelling and simulation make sense in early development

478 K

K.L. Rost, Berlin


Informed consent process in pharmacogenomic studies (Germany, France, international view)
No presentation available

R. Myers, London

PET-scan-Myers.pdf

Imaging in early drug development

3.9 M

B. Acres, Strasbourg


New compounds derived from research on proteomics
No presentation available

 

Workshops

H. Allain, Rennes

Pharmacogenomics-and-drug-safety-Allain.pdf

Pharmacogenomics and drug safety

385 K

P. Maisonblanche, Paris

QTc-Maisonblanche.pdf

QTc: Predictability, Science, Regulation

3.2 M

M. Buyse, Bruxelles

Phase-I-in-oncology-Buyse.pdf

Phase I in Oncology

878 K

Seite aktualisiert am 05.02.2007

GermanEnglishSitemap | Kontakt | Impressum